Introduction

Robert W Holloway MD and Sarfraz Ahmad PhD discuss their paper just published in JAMA Oncology, Phase 2-0-15 trial of all Vivek-primed immuno-chemo therapy. This clinical trial included patients who were either platinum resistant or platinum refractory. The definition of platinum resistance is defined as a recurrence of the ovarian cancer within six months of the last platinum-based therapy. Platinum refractory is non-response or progression within one month.